Metallothioneins (MTs) are small cysteine-rich intracellular proteins. The best-known biological functions of MTs are sequestration of metal ions and maintenance of redox homeostasis. Despite these protective functions, it has been demonstrated that MTs are involved in tumorigenesis, cellular differentiation, drug resistance, and metabolic disorders such as diabetes and obesity, in which MTs expression is substantially deregulated in adipose tissue. In addition, many studies have experimentally evidenced a possible role of MTs in the development of diabetes. Given the rich biochemical properties of MTs, it can be concluded that they are involved in several aspects of development and progression of obesity and diabetes. Thus, evaluation of expression of MTs could serve as biomarker to personalize available therapeutic interventions and possibly to develop novel advanced therapeutic modalities. Overall, the purpose of this review is analyze and review the latest studies aimed on the multiple roles of MTs in metabolic disorders, possible use of MTs as obesity and diabetes biomarkers and the role of MTs in cardioprotection during diabetes progression.

Department of Chemistry and Biochemistry Mendel University in Brno Brno Czech Republic

Therapeutic Innovation Research Center Federal University of Pernambuco Recife PE Brazil

Zobrazit více v PubMed

Kawakami T, Takasaki S, Kadota Y, Fukuoka D, Sato M, Suzuki S. Regulatory role of metallothionein-1/2 on development of sex differences in a high-fat diet-induced obesity. Life Sci. 2019;226:12–21. PubMed

Hernandez-Garcia J, Navas-Carrillo D, Orenes-Pinero E. Alterations of circadian rhythms and their impact on obesity, metabolic syndrome and cardiovascular diseases. Crit Rev Food Sci Nutr. 2020;60:1038–47. PubMed

Almendros I, Martinez-Garcia MA, Farre R, Gozal D. Obesity, sleep apnea, and cancer. Int J Obes. 2020;44:1653–67.

Lindeque JZ, van Rensburg PJJ, Louw R, van der Westhuizen FH, Florit S, Ramírez L, et al. Obesity and metabolomics: metallothioneins protect against high-fat diet-induced consequences in metallothionein knockout mice. OMICS J Integr Biol. 2015;19:92–103.

Fuster JJ, Ouchi N, Gokce N, Walsh K. Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease. CircRes. 2016;118:1786–807.

Sato M, Kawakami T, Kadota Y, Mori M, Suzuki S. Obesity and metallothionein. Curr Pharm Biotechnol. 2013;14:432–40. PubMed

Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9:367–77. PubMed PMC

Chueire VB, Muscelli E. Effect of free fatty acids on insulin secretion, insulin sensitivity and incretin effect - a narrative review. Arch Endocrinol Metab. 2021;65:24–31. PubMed

Edgerton DS, Kraft G, Smith M, Farmer B, Williams PE, Coate KC, et al. Insulin’s direct hepatic effect explains the inhibition of glucose production caused by insulin secretion. JCI Insight. 2017;2:91863. PubMed

Margoshes M, Vallee BL. A cadmium protein from equine kidney cortex. J Am Chem Soc. 1957;79:4813–4.

Morrell A, Tallino S, Yu L, Burkhead JL. The role of insufficient copper in lipid synthesis and fatty-liver disease. Iubmb Life. 2017;69:263–70. PubMed PMC

Carpene E, Andream G, Isam G. Metallothionein functions and structural characteristics. J Trace Elem Med Biol. 2007;21:35–9. PubMed

Mulder TPJ, Janssens AR, Verspaget HW, Lamers C. Plasma metallothionein concentration in patients with liver disorders - special emphasis on the relation with primary bliliary cirrhosis. Hepatology. 1991;14:1008–12. PubMed

Kiapidou S, Liava C, Kalogirou M, Akriviadis E, Sinakos E. Chronic kidney disease in patients with non-alcoholic fatty liver disease: what the Hepatologist should know?. Ann Hepatol. 2020;19:134–44. PubMed

Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908–22. PubMed PMC

Kadota Y, Toriuchi Y, Aki Y, Mizuno Y, Kawakami T, Nakaya T, et al. Metallothioneins regulate the adipogenic differentiation of 3T3-L1 cells via the insulin signaling pathway. PLoS One. 2017;12:1–18.

Cong WT, Ma WD, Zhao T, Zhu ZX, Wang YH, Tan Y, et al. Metallothionein prevents diabetes-induced cardiac pathological changes, likely via the inhibition of succinyl-CoA:3-ketoacid coenzyme A transferase-1 nitration at Trp(374). Am J Physiol Endocrinol Metab. 2013;304:826–35.

Do MS, Nam SY, Hong SE, Kim KW, Duncan JS, Beattie JH, et al. Metallothionein gene expression in human adipose tissue from lean and obese subjects. Horm Metab Res. 2002;34:348–51. PubMed

Gu JL, Cheng YL, Wu H, Kong LL, Wang SD, Xu Z, et al. Metallothionein is downstream of Nrf2 and partially mediates sulforaphane prevention of diabetic cardiomyopathy. Diabetes. 2017;66:529–42. PubMed

Gu JL, Yan XQ, Dai XZ, Wang YH, Lin Q, Xiao J, et al. Metallothionein preserves Akt2 activity and cardiac function via inhibiting TRB3 in diabetic hearts. Diabetes. 2020;69:267. PubMed

Cai L. Metallothionein as an adaptive protein prevents diabetes and its toxicity. Nonlinearity Biol Toxicol Med. 2004;2:89–103. PubMed PMC

Szrok S, Stelmanska E, Turyn J, Bielicka-Gieldon A, Sledzinski T, Swierczynski J. Metallothioneins 1 and 2, but not 3, are regulated by nutritional status in rat white adipose tissue. Genes Nutr. 2016;11:18. PubMed PMC

Liu Q, Wang S, Cai L. Diabetic cardiomyopathy and its mechanisms: Role of oxidative stress and damage. J Diab Investig. 2014;5:623–34.

Marseglia L, Manti S, D’Angelo G, Nicotera A, Parisi E, Di Rosa G, et al. Oxidative stress in obesity: a critical component in human diseases. Int J Mol Sci. 2015;16:378–400.

Manna P, Jain SK. Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: causes and therapeutic strategies. Metab Syndr Relat Disord. 2015;13:423–44. PubMed PMC

Isani G, Carpene E. Metallothioneins, unconventional proteins from unconventional animals: a long journey from nematodes to mammals. Biomolecules. 2014;4:435–57. PubMed PMC

Merlos Rodrigo MA, Krejcova L, Kudr J, Cernei N, Kopel P, Richtera L, et al. Fully automated two-step assay for detection of metallothionein through magnetic isolation using functionalized γ-Fe2O3 particles. J Chrom B. 2016;1039:17–27.

Miles AT, Hawksworth GM, Beattie JH, Rodilla V. Induction, regulation, degradation, and biological significance of mammalian metallothioneins. Crit Rev Biochem Mol Biol. 2000;35:35–70. PubMed

Juarez-Rebollar D, Rios C, Nava-Ruiz C, Mendez-Armenta M. Metallothionein in brain disorders. Oxid Med Cell Longev. 2017;2017:1–12.

Si M, Lang J. The roles of metallothioneins in carcinogenesis. J Hematol Oncol. 2018;11:1–20. PubMed PMC

Thirumoorthy N, Shyam Sunder A, Manisenthil Kumar KT, Senthil kumar M, Ganesh GNK, Chatterjee M. A review of metallothionein isoforms and their role in pathophysiology. World J Surg Oncol. 2011;9:1–7.

Takahashi S. Positive and negative regulators of the metallothionein gene (Review). Mol Med Rep. 2015;12:795–9. PubMed

Dong G, Chen H, Qi M, Dou Y, Wang Q. Balance between metallothionein and metal response element binding transcription factor 1 is mediated by zinc ions (review). Mol Med Rep. 2015;11:1582–6. PubMed

Andrews GK. Regulation of metallothionein gene expression by oxidative stress and metal ions. Biochem Pharm. 2000;59:95–104. PubMed

Kimura T, Kambe T. The functions of metallothionein and ZIP and ZnT transporters: an overview and perspective. Int J Mol Sci. 2016;17:1–22.

Laity JH, Andrews GK. Understanding the mechanisms of zinc-sensing by metal-response element binding transcription factor-1 (MTF-1). Arch Biochem Biophys. 2007;463:201–10. PubMed

Guo L, Lichten LA, Ryu MS, Liuzzi JP, Wang F, Cousins RJ. STAT5-glucocorticoid receptor interaction and MTF-1 regulate the expression of ZnT2 (Slc30a2) in pancreatic acinar cells. Proc Natl Acad Sci USA. 2010;107:2818–23. PubMed PMC

Lichten LA, Ryu MS, Guo L, Embury J, Cousins RJ. MTF-1-mediated repression of the zinc transporter Zip10 is alleviated by zinc restriction. PLoS One. 2011;6:1–12.

Fukada T, Kambe T. Molecular and genetic features of zinc transporters in physiology and pathogenesis. Metallomics. 2011;3:662–74. PubMed

Kambe T, Tsuji T, Hashimoto A, Itsumura N. The physiological, biochemical, and molecular roles of zinc transporters in zinc homeostasis and metabolism. Physiol Rev. 2015;95:749–84. PubMed

Chimienti F, Devergnas S, Pattou F, Schuit F, Garcia-Cuenca R, Vandewalle B, et al. In vivo expression and functional characterization of the zinc transporter ZnT8 in glucose-induced insulin secretion. J Cell Sci. 2006;119:4199–206. PubMed

Chimienti F, Devergnas S, Favier A, Seve M. Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. Diabetes. 2004;53:2330–7. PubMed

Huang Q, Du J, Merriman C, Gong Z. Genetic, functional, and immunological study of ZnT8 in diabetes. Int J Endocrinol. 2019;2019:1–11.

Golay A, Bobbioni E. The role of dietary fat in obesity. Int J Obes. 1997;21:2–11.

Rinella ME, Sookoian S. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. J Lipid Res. 2024;65:100485. PubMed

Liu SS, Yuan JT, Yue WH, Bi YW, Shen XY, Gao JL, et al. GCN2 deficiency protects against high fat diet induced hepatic steatosis and insulin resistance in mice. Biochim Biophys Acta Mol Basis Dis. 2018;1864:3257–67. PubMed

Grasselli E, Voci A, Demori I, De Matteis R, Compalati AD, Gallo G, et al. Effects of binge ethanol on lipid homeostasis and oxidative stress in a rat model of nonalcoholic fatty liver disease. J Physiol Biochem. 2014;70:341–53. PubMed

Martínez-Chantar ML, Avila MA, Lu SC. Hepatocellular carcinoma: updates in pathogenesis, detection and treatment. Cancers. 2020;12:2729.

Tao X, Zheng J-M, Xu A-M, Chen X-F, Zhang S-H. Downregulated expression of metallothionein and its clinicopathological significance in hepatocellular carcinoma. Hepatol Res. 2007;37:820–7. PubMed

Merlos Rodrigo MA, Jimenez Jimemez AM, Haddad Y, Bodoor K, Adam P, Krizkova S, et al. Metallothionein isoforms as double agents - their roles in carcinogenesis, cancer progression and chemoresistance. Drug Resist Updat. 2020:52:100691.

Hurt RT, Kulisek C, Buchanan LA, McClave SA. The obesity epidemic: challenges, health initiatives, and implications for gastroenterologists. Gastroenterol Hepatol. 2010;6:780–92.

Akil L, Ahmad HA. Relationships between obesity and cardiovascular diseases in four southern states and Colorado. J Health Care Poor Underserved. 2011;22:61–72. PubMed PMC

Setayesh T, Nersesyan A, Misik M, Ferk F, Langie S, Andrade VM, et al. Impact of obesity and overweight on DNA stability: Few facts and many hypotheses. Mutat Res Rev Mutat Res. 2018;777:64–91. PubMed

Davegardh C, Broholm C, Perfilyev A, Henriksen T, Garcia-Calzon S, Peijs L, et al. Abnormal epigenetic changes during differentiation of human skeletal muscle stem cells from obese subjects. BMC Med. 2017;15:1–27.

Snyder EE, Walts B, Pérusse L, Chagnon YC, Weisnagel SJ, Rankinen T, et al. The Human Obesity Gene Map: The 2003 Update. Obes Res. 2004;12:369–439. PubMed

Wang B, Wood IS, Trayhurn P. PCR arrays identify metallothionein-3 as a highly hypoxia-inducible gene in human adipocytes. Biochem Biophys Res Commun. 2008;368:88–93. PubMed PMC

Han CY. Roles of reactive oxygen species on insulin resistance in adipose tissue. Diab Metab J. 2016;40:272–9.

Castro JP, Grune T, Speckmann B. The two faces of reactive oxygen species (ROS) in adipocyte function and dysfunction. Biol Chem. 2016;397:709–24. PubMed

Jankovic A, Korac A, Buzadzic B, Otasevic V, Stancic A, Daiber A, et al. Redox implications in adipose tissue (dys)function—A new look at old acquaintances. Redox Biol. 2015;6:19–32. PubMed PMC

Wlodarczyk M, Nowicka G. Obesity, DNA damage, and development of obesity-related diseases. Int J Mol Sci. 2019;20:1–18.

O’Brien A, Kedia-Mehta N, Tobin L, Veerapen N, Besra GS, O’Shea D, et al. Targeting mitochondrial dysfunction in MAIT cells limits IL-17 production in obesity. Cell Mol Immunol. 2020;17:1193–5.

Baldini F, Fabbri R, Eberhagen C, Voci A, Portincasa P, Zischka H, et al. Adipocyte hypertrophy parallels alterations of mitochondrial status in a cell model for adipose tissue dysfunction in obesity. Life Sci. 2021;265:1–9.

Li Y, Lee SH, Piao M, Kim HS, Lee KY. Metallothionein 3 inhibits 3T3-L1 adipocyte differentiation via reduction of reactive oxygen species. Antioxidants. 2023;12:640. PubMed PMC

Nakatani Y, Kaneto H, Kawamori D, Yoshiuchi K, Hatazaki M, Matsuoka T, et al. Involvement of endoplasmic reticulum stress in insulin resistance and diabetes. J Biol Chem. 2005;280:847–51. PubMed

Ellis CD, Wang FD, MacDiarmid CW, Clark S, Lyons T, Eide DJ. Zinc and the Msc2 zinc transporter protein are required for endoplasmic reticulum function. J Cell Biol. 2004;166:325–35. PubMed PMC

Miura N, Koizumi S. Gene expression profiles in the liver and kidney of metallothionein-null mice. Biochem Biophys Res Commun. 2005;332:949–55. PubMed

Hambidge M. Human zinc deficiency. J Nutr. 2000;130:1344–9.

Konukoglu D, Turhan MS, Ercan M, Serin O. Relationship between plasma leptin and zinc levels and the effect of insulin and oxidative stress on leptin levels in obese diabetic patients. J Nutr Biochem. 2004;15:757–60. PubMed

Marreiro DD, Geloneze B, Tambascia MA, Lerario AC, Halpern A, Cozzolino SMF. Effect of zinc supplementation on serum leptin levels and insulin resistance of obese women. Biol Trace Elem Res. 2006;112:109–18. PubMed

Morais JBS, Severo JS, Beserra JB, Soares De Oiveira AR, Cruz KJC, et al. Association between cortisol, insulin resistance and zinc in obesity: a mini-review. Biol Trace Elem Res. 2019;191:323–30. PubMed

Fukunaka A, Fujitani Y. Role of zinc homeostasis in the pathogenesis of diabetes and obesity. Int J Mol Sci. 2018;19:1–14.

Fukunaka A, Fukada T, Bhin J, Suzuki L, Tsuzuki T, Takamine Y, et al. Zinc transporter ZIP13 suppresses beige adipocyte biogenesis and energy expenditure by regulating C/EBP-beta expression. PLoS Genet. 2017;13:1–23.

Zhang XQ, Zhang G, Zhang H, Karin M, Bai H, Cai DS. Hypothalamic IKK beta/NF-kappa B and ER stress link overnutrition to energy imbalance and obesity. Cell. 2008;135:61–73. PubMed PMC

Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc. 2001;60:329–39. PubMed

Habeebu SS, Liu J, Liu Y, Klaassen CD. Metallothionein-null mice are more susceptible than wild-type mice to chronic CdCl2-induced bone injury. Toxicol Sci. 2000;56:211–9. PubMed

Kawakami T, Sugimoto H, Furuichi R, Kadota Y, Inoue M, Setsu K, et al. Cadmium reduces adipocyte size and expression levels of adiponectin and Peg1/Mest in adipose tissue. Toxicology. 2010;267:20–6. PubMed

Beginheick N, Dalpescott M, Rowe J, Heick HMC. Zinc supplementation attenuates insulin secretory activity in pancreatic islets of the ob/ob mouse. Diabetes. 1985;34:179–84. PubMed

Cousins RJ, Leinart AS. Tissue-specific regulation of zinc-metabolism and metallothionein genes by interleukin-1. FASEB J. 1988;2:2884–90. PubMed

Rocha P, Amorim AD, de Sousa AF, do Monte SJH, Sousa L, Nogueira ND, et al. Expression of the zinc transporters genes and metallothionein in obese women. Biol Trace Elem Res. 2011;143:603–11.

Wang SD, Gu JL, Xu Z, Zhang ZG, Bai T, Xu JX, et al. Zinc rescues obesity-induced cardiac hypertrophy via stimulating metallothionein to suppress oxidative stress-activated BCL10/CARD9/p38 MAPK pathway. J Cell Mol Med. 2017;21:1182–92. PubMed PMC

Liang TT, Zhang Q, Sun WX, Xin Y, Zhang ZG, Tan Y, et al. Zinc treatment prevents type 1 diabetes-induced hepatic oxidative damage, endoplasmic reticulum stress, and cell death, and even prevents possible steatohepatitis in the OVE26 mouse model: Important role of metallothionein. Toxicol Lett. 2015;233:114–24. PubMed

Kamigaki M, Sakaue S, Tsujino I, Ohira H, Ikeda D, Itoh N, et al. Oxidative stress provokes atherogenic changes in adipokine gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2006;339:624–32. PubMed

Kawakami T, Nishiyama K, Kadota Y, Sato M, Inoue M, Suzuki S. Cadmium modulates adipocyte functions in metallothionein-null mice. Toxicol Appl Pharm. 2013;272:625–36.

Gasser M, Lenglet S, Bararpour N, Sajic T, Wiskott K, Augsburger M, et al. Cadmium acute exposure induces metabolic and transcriptomic perturbations in human mature adipocytes. Toxicology. 2022;470:1–12.

Young JL, Cave MC, Xu Q, Kong MY, Xu JX, Lin Q, et al. Whole life exposure to low dose cadmium alters diet-induced NAFLD. Toxicol Appl Pharm. 2022;436:1–24.

Liang YQ, Young JL, Kong MY, Tong YG, Qian Y, Freedman JH, et al. Gender differences in cardiac remodeling induced by a high-fat diet and lifelong, low-dose cadmium exposure. Chem. Res. Toxicol. 2019;32:1070–81. PubMed PMC

Zhou WQ, Young JL, Men HB, Zhang HN, Yu HT, Lin Q, et al. Sex differences in the effects of whole-life, low-dose cadmium exposure on postweaning high-fat diet-induced cardiac pathogeneses. Sci Total Environ. 2022;809:1–14.

Jahng JW, Kim JG, Kim HJ, Kang DW, Lee JH. Chronic food restriction in young rats results in depression- and anxiety-like behaviors with decreased expression of serotonin reuptake transporter. Brain Res. 2007;1150:100–7. PubMed

Kondoh M, Tsukahara R, Kuronaga M, Higashimoto M, Takiguchi M, Sato M. Enhancement of MT synthesis by leptin in fasted mice. Life Sci. 2002;71:2425–33. PubMed

Olesen RH, Hyde TM, Kleinman JE, Smidt K, Rungby J, Larsen A. Obesity and age-related alterations in the gene expression of zinc-transporter proteins in the human brain. Transl Psychiatry. 2016;6:1–8.

Swindell WR. Metallothionein and the biology of aging. Ageing Res Rev. 2011;10:132–45. PubMed

Meunier N, O’Connor JM, Maiani G, Cashman KD, Secker DL, Ferry M, et al. Importance of zinc in the elderly: the ZENITH study. Eur J Clin Nutr. 2005;59:1–4.

Takeda A. Zinc Signaling in the Hippocampus and its relation to pathogenesis of depression. Mol Neurobiol. 2011;44:166–74. PubMed

Henstridge DC, Whitham M, Febbraio MA. Chaperoning to the metabolic party: the emerging therapeutic role of heat-shock proteins in obesity and type 2 diabetes. Mol Metab. 2014;3:781–93. PubMed PMC

Habich C, Sell H. Heat shock proteins in obesity: links to cardiovascular disease. Horm Mol Biol Clin Investig. 2015;21:117–24. PubMed

Kaur P, Reis MD, Couchman GR, Forjuoh SN, Greene JF, Asea A. Role of heat shock proteins in obesity and type 2 diabetes. In: Asea AAA, Pedersen BK, editors. Heat shock proteins and whole body physiology. Heat Shock Proteins, Springer, Dordrecht; 52010. p. 19–29. https://doi.org/10.1007/978-90-481-3381-9_2 .

Mardan-Nik M, Pasdar A, Jamialahmadi K, Avan A, Mohebati M, Esmaily H, et al. Association of heat shock protein70-2 (HSP70-2) gene polymorphism with obesity. Ann Hum Biol. 2016;43:542–6. PubMed

Sabbah NA, Rezk NA, Saad MSS. Relationship between heat shock protein expression and obesity with and without metabolic syndrome. Genet Test Mol Biomark. 2019;23:737–43.

Kim S, Sohn I, Ahn J-I, Lee K-H, Lee YS, Lee YS. Hepatic gene expression profiles in a long-term high-fat diet-induced obesity mouse model. Gene. 2004;340:99–109. PubMed

Timofeev YS, Kiselev AR, Dzhioeva ON, Drapkina OM. Heat shock proteins (HSPs) and cardiovascular complications of obesity: searching for potential biomarkers. Curr Issues Mol Biol. 2023;45:9378–89. PubMed PMC

Tiss A, Khadir A, Abubaker J, Abu-Farha M, Al-Khairi I, Cherian P, et al. Immunohistochemical profiling of the heat shock response in obese non-diabetic subjects revealed impaired expression of heat shock proteins in the adipose tissue. Lipids Health Dis. 2014;13:106. PubMed PMC

Lee KY, Kim SJ, Cha YS, So JR, Park JS, Kang KS, et al. Effect of exercise on hepatic gene expression in an obese mouse model using cDNA microarrays. Obesity. 2006;14:1294–302. PubMed

Chiang JL, Kirkman MS, Laffel LMB, Peters AL. Type 1 Diabetes Sourcebook A. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diab Care. 2014;37:2034–54.

Zhang PH, Chen ZW, Lv D, Xu YY, Gu WL, Zhang XH, et al. Increased risk of cancer in patients with type 2 diabetes mellitus: a retrospective cohort study in China. BMC Public Health. 2012;12:1–6.

Lascar N, Brown J, Pattison H, Barnett AH, Bailey CJ, Bellary S. Type 2 diabetes in adolescents and young adults. Lancet Diab Endocrinol. 2018;6:69–80.

Reinehr T, Wabitsch M. Type 2 diabetes mellitus in children and adolescents. Oxford: Blackwell Science Publ; 2005. pp. 21–40.

Campbell-Thompson M, Rodriguez-Calvo T, Battaglia M. Abnormalities of the exocrine pancreas in type 1 diabetes. Curr Diab Rep. 2015;15:79. PubMed PMC

Mao YX, Tao M, Jia XY, Xu H, Chen K, Tang HW, et al. Effect of diabetes mellitus on survival in patients with pancreatic cancer: a systematic review and meta-analysis. Sci Rep. 2015;5:1–11.

Zou X, Hu M, Huang X, Zhou L, Li M, Chen J, et al. Rare variant in metallothionein 1E increases the risk of type 2 diabetes in a Chinese population. Diab Care. 2023;46:2249–57.

Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diab-Metab Res Rev. 2001;17:189–212.

Matough FA, Budin SB, Hamid ZA, Alwahaibi N, Mohamed J. The role of oxidative stress and antioxidants in diabetic complications. Sultan Qaboos Univ Med J. 2012;12:5–18. PubMed PMC

Maiese K, Chong ZZ, Shang YC. Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem. 2007;14:1729–38. PubMed PMC

Slepchenko KG, Chen S, Counts GP, Corbin KL, Colvin RA, Nunemaker CS. Synchrotron fluorescence imaging of individual mouse beta-cells reveals changes in zinc, calcium, and iron in a model of low-grade inflammation. Metallomics. 2021;13:1–10.

Wang K, Dai XZ, He JH, Yan XQ, Yang CK, Fan X, et al. Endothelial overexpression of metallothionein prevents diabetes-induced impairment in ischemia angiogenesis through preservation of HIF-1 alpha/SDF-1/VEGF signaling in endothelial progenitor cells. Diabetes. 2020;69:1779–92. PubMed PMC

Ruttkay-Nedecky B, Nejdl L, Gumulec J, Zitka O, Masarik M, Eckschlager T, et al. The role of metallothionein in oxidative stress. Int J Mol Sci. 2013;14:6044–66. PubMed PMC

Wei W, Liu QJ, Tan Y, Liu LC, Li XK, Cai L. Oxidative stress, diabetes and diabetic complications. Hemoglobin. 2009;33:370–7. PubMed

Bensellam M, Laybutt DR, Jonas JC. Emerging roles of metallothioneins in beta cell pathophysiology: beyond and above metal homeostasis and antioxidant response. Biology. 2021;10:1–21.

Raudenska M, Gumulec J, Podlaha O, Sztalmachova M, Babula P, Eckschlager T, et al. Metallothionein polymorphisms in pathological processes. Metallomics. 2014;6:55–68. PubMed

MacKenzie S, Bergdahl A. Zinc homeostasis in diabetes mellitus and vascular complications. Biomedicines. 2022;10:1–14.

Taylor CG. Zinc, the pancreas, and diabetes: insights from rodent studies and future directions. Biometals. 2005;18:305–12. PubMed

Tallman DL, Taylor CG. Potential interactions of zinc in the neuroendocrine-endocrine disturbances of diabetes mellitus type 2. Can J Physiol Pharm. 1999;77:919–33.

Mondragon P, Bergdahl A. Metallothionein expression in slow- vs. fast-twitch muscle fibers following 4 weeks of streptozotocin-induced type 1 diabetes. FACETS. 2018;3:315–25.

Chen ML, Failla ML. Metallothionein metabolism in the liver and kidney of the streptozotocin-diabetic rat. Comp Biochem Physiol B Biochem Mol Biol. 1988;90:439–45.

Coyle P, Philcox JC, Carey LC, Rofe AM. Metallothionein: the multipurpose protein. Cell Mol Life Sci. 2002;59:627–47. PubMed PMC

Yang YP, Cherian MG. Protective effects of metallothionein on streptozotocin-induced diabetes in rats. Life Sci. 1994;55:43–51. PubMed

Sato M, Kawakami T, Kondoh M, Takiguchi M, Kadota Y, Himeno S, et al. Development of high-fat-diet-induced obesity in female metallothionein-null mice. FASEB J. 2010;24:2375–84. PubMed

Haynes V, Connor T, Tchernof A, Vidal H, Dubois S. Metallothionein 2a gene expression is increased in subcutaneous adipose tissue of type 2 diabetic patients. Mol Genet Metab. 2013;108:90–4. PubMed

Tachibana H, Ogawa D, Sogawa N, Asanuma M, Miyazaki I, Terami N, et al. Metallothionein deficiency exacerbates diabetic nephropathy in streptozotocin-induced diabetic mice. Am J Physiol Ren Physiol. 2014;306:105–15.

Bensellam M, Shi Y-C, Chan JY, Laybutt DR, Chae H, Abou-Samra M, et al. Metallothionein 1 negatively regulates glucose-stimulated insulin secretion and is differentially expressed in conditions of beta cell compensation and failure in mice and humans. Diabetologia. 2019;62:2273–86. PubMed

Ogawa D, Asanuma M, Miyazaki I, Tachibana H, Wada J, Sogawa N, et al. High glucose increases metallothionein expression in renal proximal tubular epithelial cells. Exp Diab Res. 2011;2011:534872.

Lu Y, Zhang YX, Lou Y, Cui WP, Miao LN. Sulforaphane suppresses obesity-related glomerulopathy-induced damage by enhancing autophagy via Nrf2. Life Sci. 2020;258:1–7.

Heger Z, Rodrigo MAM, Krizkova S, Ruttkay-Nedecky B, Zalewska M, del Pozo EMP, et al. Metallothionein as a scavenger of free radicals - new cardioprotective therapeutic agent or initiator of tumor chemoresistance?. Curr Drug Targets. 2016;17:1438–51. PubMed

Cong WT, Zhao T, Zhu ZX, Huang BB, Ma WD, Wang YH, et al. Metallothionein prevents cardiac pathological changes in diabetes by modulating nitration and inactivation of cardiac ATP synthase. J Nutr Biochem. 2014;25:463–74. PubMed

Zhou SS, Yin X, Zheng Y, Miao X, Feng WK, Cai J, et al. Metallothionein prevents intermittent hypoxia-induced cardiac endoplasmic reticulum stress and cell death likely via activation of Akt signaling pathway in mice. Toxicol Lett. 2014;227:113–23. PubMed

Byrne NJ, Rajasekaran NS, Abel ED, Bugger H. Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy. Free Radic Biol Med. 2021;169:317–42. PubMed PMC

Aroor AR, Mandavia CH, Sowers JR. Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin. 2012;8:609–17. PubMed PMC

James PT, Rigby N, Leach R. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil. 2004;11:3–8. PubMed

Sharma AM, Chetty VT. Obesity, hypertension and insulin resistance. Acta Diabetol. 2005;42:3–8.

Hu LJ, Qiu C, Wang XS, Xu M, Shao XL, Wang YT. The association between diabetes mellitus and reduction in myocardial glucose uptake: a population-based F-18-FDG PET/CT study. BMC Cardiovasc Disord. 2018;18:1–8.

Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 2005;59:365–73. PubMed

Wang J, Song Y, Elsherif L, Song Z, Zhou G, Prabhu Sumanth D, et al. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation. 2006;113:544–54. PubMed

Huang S, Wang JQ, Men HB, Tan Y, Lin Q, Gozal E, et al. Cardiac metallothionein overexpression rescues diabetic cardiomyopathy in Akt2-knockout mice. J Cell Mol Med. 2021;25:6828–40. PubMed PMC

Song Y, Wang JX, Li Y, Du YB, Arteel GE, Saari JT, et al. Cardiac metallothionein synthesis in streptozotocin-induced diabetic mice, and its protection against diabetes-induced cardiac injury. Am J Pathol. 2005;167:17–26. PubMed PMC

Giacconi R, Bonfigli AR, Testa R, Sirolla C, Cipriano C, Marra M, et al. +647 A/C and +1245 MT1A polymorphisms of diabetes mellitus and cardiovascular in the susceptibility complications. Mol Genet Metab. 2008;94:98–104. PubMed

Kumar V, Singh J, Bala K, Singh J. Association of metallothionein 1A gene polymorphisms at rs11640851 and rs8052394 with risk of type 2 diabetes mellitus in Indian population. Meta Gene. 2021;28:1–5.

Kozarova R, Postadzhiyan A, Apostolova MD. Association of+1245 A/G MT1A and-209 A/G MT2A polymorphysms with coronary artery disease and diabetes mellitus in Bulgarian cohort. Biotechnol Biotechnol Equip. 2012;26:100–6.

Cai L. Suppression of nitrative damage by metallothionein in diabetic heart contributes to the prevention of cardiomyopathy. Free Radic Biol Med. 2006;41:851–61. PubMed

Liang QR, Carlson EC, Donthi RV, Kralik PM, Shen X, Epstein PN. Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes. 2002;51:174–81. PubMed

Sun WX, Miao X, Zhou SS, Zhang L, Epstein PN, Mellen N, et al. Zinc rescue of Akt2 gene deletion-linked murine cardiac dysfunction and pathological changes is metallothionein-dependent. J Mol Cell Cardiol. 2014;74:88–97. PubMed

Xu J, Wang G, Wang Y, Liu Q, Xu W, Tan Y, et al. Diabetes- and angiotensin II-induced cardiac endoplasmic reticulum stress and cell death: metallothionein protection. J Cell Mol Med. 2009;13:1499–512. PubMed PMC

Zhou GH, Li XK, Hein DW, Xiang XL, Marshall JP, Prabhu SD, et al. Metallothionein suppresses angiotensin II-Induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. J Am Coll Cardiol. 2008;52:655–66. PubMed

Xue WL, Liu Y, Zhao J, Cai L, Li X, Feng W. Activation of HIF-1 by metallothionein contributes to cardiac protection in the diabetic heart. Am J Physiol Heart Circ Physiol. 2012;302:2528–35.

Dong F, Li Q, Sreejayan N, Nunn JM, Ren J. Metallothionein prevents high-fat diet–induced cardiac contractile dysfunction. Diabetes. 2007;56:1–12.

Yu L, Liu Y, Jin Y, Liu T, Wang W, Lu X, et al. Zinc supplementation prevented type 2 diabetes-induced liver injury mediated by the Nrf2-MT antioxidative pathway. J Diab Res. 2021;2021:1–14.

Wang YH, Feng WK, Xue WL, Tan Y, Hein DW, Li XK, et al. Inactivation of GSK-3 beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling. Diabetes. 2009;58:1391–402. PubMed PMC

Van Hove I, De Groef L, Boeckx B, Modave E, Hu TT, Beets K, et al. Single-cell transcriptome analysis of the Akimba mouse retina reveals cell-type-specific insights into the pathobiology of diabetic retinopathy. Diabetologia. 2020;63:2235–48. PubMed

Xue M, Joo YA, Li ST, Niu C, Chen G, Yi XC, et al. Metallothionein Protects the Heart Against Myocardial Infarction via the mTORC2/FoxO3a/Bim Pathway. Antioxid Redox Signal. 2019;31:403–19. PubMed

Ohly P, Dohle C, Abel J, Seissler J, Gleichmann H. Zinc sulphate induces metallothionein in pancreatic islets of mice and protects against diabetes induced by multiple low doses of streptozotocin. Diabetologia. 2000;43:1020–30. PubMed

Ho E, Quan N, Tsai YH, Lai W, Bray TM. Dietary zinc supplementation inhibits NFkappaB activation and protects against chemically induced diabetes in CD1 mice. Exp Biol Med. 2001;226:103–11.

Chen H, Carlson EC, Pellet L, Moritz JT, Epstein PN. Overexpression of metallothionein in pancreatic beta-cells reduces streptozotocin-induced DNA damage and diabetes. Diabetes. 2001;50:2040–6. PubMed

Costarelli L, Muti E, Malavolta M, Cipriano C, Giacconi R, Tesei S, et al. Distinctive modulation of inflammatory and metabolic parameters in relation to zinc nutritional status in adult overweight/obese subjects. J Nutritional Biochem. 2010;21:432–7.

Mota Martins L, Soares de Oliveira AR, Clímaco Cruz KJ, Borges de Araújo CG, de Oliveira FE, Santos de Sousa G, et al. Influence of cortisol on zinc metabolism in morbidly obese women. Nutr Hosp. 2014;29:57–63. PubMed

Sylaja PN, Srivastava MVP, Shah S, Bhatia R, Khurana D, Sharma A, et al. The SARS-CoV-2/COVID-19 pandemic and challenges in stroke care in India. Ann N Y Acad Sci. 2020;1473:3–10. PubMed PMC

Simon Abadia C. COVID-19, a graphic account. Emergencias. 2020;32:206–9. PubMed

Mahase E. Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction. BMJ. 2020;368:1.

Muralidar S, Ambi SV, Sekaran S, Krishnan UM. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie. 2020;179:85–100. PubMed PMC

Di Stadio A, Ricci G, Greco A, de Vincentiis M, Ralli M. Mortality rate and gender differences in COVID-19 patients dying in Italy: a comparison with other countries. Eur Rev Med Pharm Sci. 2020;24:4066–7.

Zakka K, Chidambaram S, Mansour S, Mahawar K, Salminen P, Almino R, et al. SARS-CoV-2 and obesity: “CoVesity”—a pandemic within a pandemic. Obes Surg. 2021;31:1745–54. PubMed PMC

Lisco G, De Tullio A, Giagulli VA, Guastamacchia E, De Pergola G, Triggiani V. Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review. Endocrine. 2020;70:441–53. PubMed PMC

Bae S, Kim SR, Kim M-N, Shim WJ, Park S-M. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart. 2021;107:1–8.

Lim S, Bae JH, Kwon H-S, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17:11–30. PubMed

McGurnaghan SJ, Weir A, Bishop J, Kennedy S, Blackbourn LAK, McAllister DA, et al. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diab Endocrinol. 2021;9:82–93.

Unnikrishnan R, Misra A. Diabetes and COVID19: a bidirectional relationship. Nutr Diab. 2021;11:1–5.

Al-Sabah S, Al-Haddad M, Al-Youha S, Jamal M, Almazeedi S. COVID-19: Impact of obesity and diabetes on disease severity. Clin Obes. 2020;10:1–6.

Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: distinct or continuum?. Indian J Endocrinol Metab. 2016;20:546–51. PubMed PMC

Carey IM, Critchley JA, DeWilde S, Harris T, Hosking FJ, Cook DG. Risk of infection in type 1 and type 2 diabetes compared with the general population: a matched cohort study. Diab Care. 2018;41:1–9.

Pelle MC, Zaffina I, Provenzano M, Moirano G, Arturi F. COVID-19 and diabetes—two giants colliding: From pathophysiology to management. Front Endocrinol. 2022;13:1–13.

Pfortmueller CA, Spinetti T, Urman RD, Luedi MM, Schefold JC. COVID-19-associated acute respiratory distress syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment – a narrative review. Best Pract Res Clin Anaesthesiol. 2021;35:351–68.

Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diab Endocrinol. 2022;10:311–21.

van der Heide V, Jangra S, Cohen P, Rathnasinghe R, Aslam S, Aydillo T, et al. Limited extent and consequences of pancreatic SARS-CoV-2 infection. Cell Rep. 2022;38:1–28.

Boudreault F, Pinilla-Vera M, Englert JA, Kho AT, Isabelle C, Arciniegas AJ, et al. Zinc deficiency primes the lung for ventilator-induced injury. JCI Insight. 2017;2:1–15.

Jarosz M, Olbert M, Wyszogrodzka G, Młyniec K, Librowski T. Antioxidant and anti-inflammatory effects of zinc. Zinc-dependent NF-κB signaling. Inflammopharmacology. 2017;25:11–24. PubMed PMC

Rahman MT, Karim MM. Metallothionein: a Potential Link in the Regulation of Zinc in Nutritional Immunity. Biol Trace Elem Res. 2018;182:1–13. PubMed

Subramanian Vignesh K, Deepe GS Jr. Metallothioneins: Emerging Modulators in Immunity and Infection. Int J Obes. 2017;18:1–25.

Sethuram R, Bai D, Abu-Soud HM. Potential Role of Zinc in the COVID-19 Disease Process and its Probable Impact on Reproduction. Reprod Sci. 2022;29:1–6. PubMed

Su YP, Chen D, Yuan D, Lausted C, Choi J, Dai CZL, et al. Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. Cell. 2020;183:1479. PubMed PMC

Herrera-Quintana L, Vázquez-Lorente H, Gamarra-Morales Y, Molina-López J, Planells E. Evolution of Status of Trace Elements and Metallothioneins in Patients with COVID-19: Relationship with Clinical, Biochemical, and Inflammatory Parameters. Metabolites. 2023;13.

Rahmani-Kukia N, Abbasi A, Pakravan N, Hassan ZM. Measurement of oxidized albumin: an opportunity for diagnoses or treatment of COVID-19. Bioorganic Chem. 2020;105:104429.

Abouhashem AS, Singh K, Azzazy HME, Sen CK. Is low alveolar type II cell SOD3 in the lungs of elderly linked to the observed severity of COVID-19?. Antioxid Redox Signal. 2020;33:59–65. PubMed PMC

Cabrera AJR. Zinc, aging, and immunosenescence: an overview. Pathobiol Aging Age Relat Dis. 2015;5:25592. PubMed

Uwitonze AM, Ojeh N, Murererehe J, Atfi A, Razzaque MS. Zinc adequacy is essential for the maintenance of optimal oral health. Nutrients. 2020;12:1–14.

Tsuchiya H. Gustatory and saliva secretory dysfunctions in COVID-19 patients with zinc deficiency. Life. 2022;12:1–26.

Singh S, Diwaker A, Singh BP, Singh RK. Nutritional immunity, zinc sufficiency, and COVID-19 mortality in socially similar European populations. Front Immunol. 2021;12:1–10.

Livanos AE, Jha D, Cossarini F, Gonzalez-Reiche AS, Tokuyama M, Aydillo T, et al. Intestinal host response to SARS-CoV-2 infection and COVID-19 outcomes in patients with gastrointestinal symptoms. Gastroenterology. 2021;160:2435–50. PubMed

Sumaily KM. The roles and pathogenesis mechanisms of a number of micronutrients in the prevention and/or treatment of chronic hepatitis, COVID-19 and type-2 diabetes mellitus. Nutrients. 2022;14:2632.

Vijay J, Gauthier MF, Biswell RL, Louiselle DA, Johnston JJ, Cheung WA, et al. Single-cell analysis of human adipose tissue identifies depot- and disease-specific cell types. Nat Metab. 2020;2:97–109. PubMed

Puerta M, Abelenda M, Rocha M, Trayhurn P. Effect of acute cold exposure on the expression of the adiponectin, resistin and leptin genes in rat white and brown adipose tissues. Horm Metab Res. 2002;34:629–34. PubMed

Gomez-Santos C, Hernandez-Morante JJ, Margareto J, Larrarte E, Formiguera X, Martinez CM, et al. Profile of adipose tissue gene expression in premenopausal and postmenopausal women: site-specific differences. Menopause. 2011;18:675–84. PubMed